Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Incyte’s latest 10-K means sifting through pages of clinical-trial data, FDA milestones, and royalty tables—details that can obscure crucial signals like how much Jakafi revenue offsets soaring R&D costs. If finding Incyte insider trading Form 4 transactions before a pivotal read-out feels daunting, you’re not alone.
Stock Titan’s AI reads every Incyte quarterly earnings report 10-Q filing, 8-K material events explained, and the full Incyte annual report 10-K simplified so you don’t have to. Our platform delivers real-time alerts the moment an Incyte Form 4 insider transactions real-time notice posts to EDGAR, then translates legal jargon into plain English. Need a quick brief on trial spend vs. cash reserves? Our AI-powered summaries surface it in one click, making understanding Incyte SEC documents with AI part of your routine.
Use the filing types below to answer the questions professionals ask every quarter:
- 10-Q: Track segment revenue, pipeline spend, and compare results with our Incyte earnings report filing analysis.
- 10-K: Review patent cliffs, market-size assumptions, and risk factors�Incyte SEC filings explained simply.
- Form 4: Monitor Incyte executive stock transactions Form 4 for buying or selling patterns.
- DEF 14A: See the Incyte proxy statement executive compensation section without hunting through tables.
- 8-K: Get Incyte 8-K material events explained within minutes of release.
Whether you’re gauging partnership royalty streams or confirming cash runway, Stock Titan turns dense biotech disclosures into actionable knowledge—before the market reacts.
On 07/21/2025, Steven H. Stein, EVP & Chief Medical Officer of Incyte Corp. (INCY), filed a Form 4 reporting the sale of 3,706 common shares at $67.94 per share (� $252 k gross proceeds). After the transaction, Stein still beneficially owns 102,886 shares, a figure that includes 100,327 unvested restricted stock units and earned performance shares disclosed in footnote 1. No derivative securities were acquired or disposed of in this filing and no additional transactions were reported.
The filing represents a routine insider sale amounting to roughly 3.6 % of Stein’s post-transaction holding. There is no indication of option exercise, stock-for-tax withholding, or special circumstances; therefore, investment impact appears limited.
Luther King Capital Management Corp. (LKCM) and its founder, J. Luther King, Jr., have filed Amendment No. 6 to Schedule 13G for scPharmaceuticals Inc. (SCPH) dated 30 Jun 2025. The filing discloses continued beneficial ownership above the 5 % threshold:
- LKCM reports 3,541,170 common shares with sole voting and dispositive power, representing 6.7 % of SCPH’s outstanding stock.
- J. Luther King, Jr. individually reports 3,669,170 common shares (sole voting/dispositive power) for a 7.0 % stake.
The amendment confirms that the shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. Both reporting persons classify as an “Investment Adviser� (LKCM) and “Individual� (King) under Rule 13d-1(b). No joint filing or group status is claimed, and there are no shared voting or dispositive powers.
Implications for investors: 1) LKCM remains one of SCPH’s larger institutional holders, potentially signaling confidence in the company’s prospects. 2) Because the ownership level is stable at ~7 %, the amendment itself does not suggest an imminent change in strategic direction or control. 3) Any future movement above or below the 5 % threshold would trigger additional filings, providing transparency on LKCM’s trading activity.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
What is Incyte Corp's primary focus?
How does Incyte generate revenue?
What therapeutic areas does Incyte primarily target?
How does Incyte differentiate itself in the competitive biopharmaceutical industry?
What is unique about Incyte's drug development approach?
Can you explain Incyte's role in addressing unmet medical needs?
What are some of the key products in Incyte's portfolio?
What role do strategic partnerships play at Incyte?
